A Swiss-based diagnostics company, spun off from a university, engaged with DIAMANTE following the completion of their Discovery program in cancer diagnostics, which yielded a set of promising biomarker candidates.
DIAMANTE provided fractional management support to guide the company through the critical next phases of development. This began with an independent assessment of the company’s assets and strategic prioritization of the most promising biomarker candidates based on their clinical and commercial potential.
Specifically, DIAMANTE contributed to the planning of validation studies to advance prioritized biomarkers toward clinical utility, while providing strategic input into the company’s fundraising efforts. This included guidance on identifying and engaging potential new investors, preparing comprehensive due diligence materials, and shaping investor pitch decks and a structured data room to facilitate an efficient and professional fundraising process.